Frontiers in Medicine (Apr 2023)

Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome

  • Max Augustin,
  • Max Augustin,
  • Max Augustin,
  • Ferdinand Heyn,
  • Ferdinand Heyn,
  • Ferdinand Heyn,
  • Stella Ullrich,
  • Stella Ullrich,
  • Stella Ullrich,
  • Ute Sandaradura de Silva,
  • Ute Sandaradura de Silva,
  • Ute Sandaradura de Silva,
  • Marie-Christine Albert,
  • Marie-Christine Albert,
  • Viktoria Linne,
  • Maike Schlotz,
  • Maike Schlotz,
  • Philipp Schommers,
  • Philipp Schommers,
  • Philipp Schommers,
  • Philipp Schommers,
  • Elisabeth Pracht,
  • Carola Horn,
  • Carola Horn,
  • Carola Horn,
  • Isabelle Suarez,
  • Isabelle Suarez,
  • Alexander Simonis,
  • Alexander Simonis,
  • Alexander Simonis,
  • Lea Katharina Picard,
  • Lea Katharina Picard,
  • Alexander Zoufaly,
  • Alexander Zoufaly,
  • Christoph Wenisch,
  • Gerd Fätkenheuer,
  • Gerd Fätkenheuer,
  • Henning Gruell,
  • Henning Gruell,
  • Florian Klein,
  • Florian Klein,
  • Florian Klein,
  • Michael Hallek,
  • Henning Walczak,
  • Henning Walczak,
  • Henning Walczak,
  • Jan Rybniker,
  • Jan Rybniker,
  • Jan Rybniker,
  • Sebastian J. Theobald,
  • Sebastian J. Theobald,
  • Sebastian J. Theobald,
  • Clara Lehmann,
  • Clara Lehmann,
  • Clara Lehmann

DOI
https://doi.org/10.3389/fmed.2023.1129288
Journal volume & issue
Vol. 10

Abstract

Read online

BackgroundSymptoms lasting longer than 12 weeks after severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection are called post-coronavirus disease (COVID) syndrome (PCS). The identification of new biomarkers that predict the occurrence or course of PCS in terms of a post-viral syndrome is vital. T-cell dysfunction, cytokine imbalance, and impaired autoimmunity have been reported in PCS. Nevertheless, there is still a lack of conclusive information on the underlying mechanisms due to, among other things, a lack of controlled study designs.MethodsHere, we conducted a prospective, controlled study to characterize the humoral and cellular immune response in unvaccinated patients with and without PCS following SARS-CoV-2 infection over 7 months and unexposed donors.ResultsPatients with PCS showed as early as 6 weeks and 7 months after symptom onset significantly increased frequencies of SARS-CoV-2-specific CD4+ and CD8+ T-cells secreting IFNγ, TNF, and expressing CD40L, as well as plasmacytoid dendritic cells (pDC) with an activated phenotype. Remarkably, the immunosuppressive counterparts type 1 regulatory T-cells (TR1: CD49b/LAG-3+) and IL-4 were more abundant in PCS+.ConclusionThis work describes immunological alterations between inflammation and immunosuppression in COVID-19 convalescents with and without PCS, which may provide potential directions for future epidemiological investigations and targeted treatments.

Keywords